Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition
-- Two dose levels studied (100 and 300 million CAR+ T-cells); MTD not reached -- -- 100% ORR at both...